Kendrekar Drug Development for Malaria

Novel Approaches for Prevention and Treatment
1. Auflage 2022
ISBN: 978-3-527-83059-6
Verlag: Wiley-VCH
Format: EPUB
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 400 Seiten, E-Book

This systematic overview of antimalarial drug development addresses current challenges and opportunities and presents numerous case studies for the successful development of effective novel antimalarials.

Autoren/Hrsg.

Kendrekar, Pravin

Inhaltsverzeichnis

INTRODUCTION
Past, Present and Future Drug Development for Malaria
 
CHALLENGES AND OPPORTUNITIES IN MALARIA THERAPY
Scientific Challenges and Treatment Opportunities in the Face of Shifting Malaria Epidemiology
Emerging Formulation Technologies against Malaria Resurgence
Targeted Drug Delivery for Malarial Therapy
The Imminent Threat of Antimalarial Drug Resistance
Current Therapies and New Drug Targets for the Future Drug Development of Drug Resistant Malaria
 
DRUG DEVELOPMENT
Assays for Antimalarial Drug Discovery
Aminoacyl-tRNA Synthetases as Malarial Drug Targets: A Structural Biology Perspective
Natural Products as a Source for Antimalarial Drug Development Process - An Overview
Mushroom-Derived Products as an Alternative Antimalarial Therapeutics: A Review
Discovery and Trends of 8-Aminoquinoline and 4-Aminoquinoline Classes of Antimalarials
Antimalarial Activity of Novel Class of 1,3-Benzoxaborole Derivatives Containing 1, 3, 4-Oxadiazole Moiety
 
VACCINE PERSPECTIVE
Recent Advances in Malaria Vaccine Development
Toll-Like Receptor-Based Adjuvants - A Gateway Towards Improved Malaria Vaccination
Pure TLR7 Agonistic BBIQ is a Potential Adjuvant against P. Berghei ANKA Challenge in Vivo

Über Autor(innen)

Pravin Kendrekar studied chemistry at Swami Ramanand Teerth Marathwada University (India) and completed his Ph.D. in Organic Chemistry at Nagoya University of Technology (Japan). After post-doctoral work at Ben Gurion University (Israel) and the University of the Free State (South Africa), he joined the Central University of Technology at Bloemfontein (South Africa) in 2017, where he is currently a group leader in the Unit for Drug Discovery Research. The primary focus of his work is in antimalarial therapy.